Compare CSX Corporation (CSX) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Cytokinetics Inc — how do they compare? CSX Corporation trades at $47.6 (market cap $87.70B), while Cytokinetics Inc trades at $61.95 (market cap $8.62B). The key difference: CSX Corporation is far larger — about 10.2× Cytokinetics Inc's market cap, and CSX Corporation pays a 1.18% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Cytokinetics Inc for 19 Days on average.
| CSX | CYTK | |
|---|---|---|
Market Cap | $87.70B | $8.62B |
Volume | 6,980,781 | 2,594,626 |
Sector | Industrials | Health |
52-Week High | $53.21 | $87.26 |
52-Week Low | $33.68 | $54.76 |
Typical Hold Time | 55 Days | 19 Days |
Enterprise Value | $105.66B | $8.72B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $46.81, down 1.45% today, with a bearish technical signal from moving averages. The company reported mixed quarterly EPS results, missing in Q4 2025 but beating in Q1 and Q2 2026. Revenue has declined from $14.9B in 2022 to $14.1B in 2025, though 2026 projections show a rebound to $14.5B. Analyst consensus is bullish with a $51 price target, supported by strong institutional buying activity reported in recent SEC filings.
The outlook for CSX hinges on earnings recovery and operational efficiency gains. Key opportunities include pricing power in freight rail and dividend growth, while risks involve revenue volatility and high debt levels. The stock offers potential upside to the consensus target but faces headwinds from economic cycles affecting freight demand.
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
